Skip to main content
SEOUL PHARMA CO.,LTD logo

SEOUL PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 018680 ISIN · KR7018680009 KO Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2020-03-11 AGM Information
Country KR South Korea
Listing KO 018680

About SEOUL PHARMA CO.,LTD

http://www.seoulpharmaceuticals.com/

Seoul Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in innovative drug delivery systems, with a core competency in Orally Disintegrating Film (ODF) technology. Its product portfolio includes a wide range of prescription and over-the-counter medications. Key therapeutic areas cover cardiovascular and respiratory systems, as well as anti-infective agents such as antibacterials, antifungals, and antivirals. The company also produces vitamins and antibiotics, aiming to improve health outcomes through its cutting-edge technological capabilities.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Seoul Pharma. It contains the meeting agenda, details on board elections, financial statements (balance sheet and income statement), and management's discussion of business operations. This type of document is standard for providing shareholders with the necessary information to vote at an upcoming AGM. It is not a standalone report publication announcement (RPA) because it contains the full meeting agenda and financial data required for the meeting itself, fitting the definition of Proxy Solicitation & Information Statement (PSI) or AGM-related materials.
2020-03-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the acquisition of shares and convertible bonds by '2018 QCP 13th Private Equity Fund' in 'Seoul Pharma'. This type of filing is specifically used to notify the market of significant changes in share ownership (crossing the 5% threshold), which falls under the 'Major Shareholding Notification' category.
2020-03-04 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a formal 'Major Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). This type of filing details capital structure changes, financing terms, and specific debt instruments. According to the provided definitions, documents detailing fundraising, financing activities, or capital structure changes are classified as 'CAP'.
2020-02-28 Korean
최대주주변경을수반하는주식양수도계약체결
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from a Korean company (Seoul Pharma) announcing a 'Change in Largest Shareholder' due to a stock purchase agreement. This type of disclosure is a standard corporate event announcement regarding ownership structure changes. Since it does not fit into specific categories like 'Director's Dealing' (which is for individual insider trades) or 'Major Shareholding Notification' (which is usually filed by the investor), it falls under the general regulatory filing category for corporate announcements.
2020-02-28 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for Seoul Pharma, detailing the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This document is a solicitation of shareholder participation and information regarding the meeting, which falls under the Proxy Solicitation & Information Statement category.
2020-02-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Seoul Pharma) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in Korea (often referred to as a 'Fair Disclosure' or 'Significant Change' filing) that provides key financial highlights before the final audit is completed. It fits the definition of an Earnings Release (ER) as it provides the initial announcement of financial results and key highlights.
2020-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.